MegaPro Biomedical Co., Ltd.

As of June 30, 2026, MegaPro Biomedical Co., Ltd. carries a market capitalization of 979.73M, placing it among publicly traded companies globally. Its enterprise value stands at 893.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MegaPro Biomedical Co., Ltd. has 79.33M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MegaPro Biomedical Co., Ltd. maintains a current ratio of 14.17, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, MegaPro Biomedical Co., Ltd.'s stock has declined approximately 5.29% over the past 52 weeks. The 50-day moving average sits at 11.80, while the 200-day moving average is 11.84.

As of June 30, 2026, MegaPro Biomedical Co., Ltd. holds 87.58M in cash and equivalents against 1.46M in total debt, resulting in a net debt position of -87.56M. Total book value stands at 217.71M, with working capital of 205.25M providing operational flexibility.

MegaPro Biomedical Co., Ltd.'s most recent stock split took place on September 11, 2025 with a 599:641 split ratio.